---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-028809"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:50:46.461159+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Theravance settles YUPELRI patent litigation with Lupin; generic launch delayed to April 23, 2039

## Summary
- Settlement grants Lupin a royalty-free, non-exclusive license to market generic revefenacin starting April 23, 2039.
- The settlement resolves ongoing Hatch-Waxman litigation based on Lupin's ANDA for YUPELRI.
- Patent litigation continues against three other ANDA filers: Cipla, Eugia Pharma, and Mankind Pharma.
- Settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

## SEC filing metadata
- accession: 0001104659-24-028809
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465924028809/0001104659-24-028809-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465924028809/tm247495d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-028809
- JSON: https://secwatch.observer/filing/0001104659-24-028809.json
- Plain text: https://secwatch.observer/filing/0001104659-24-028809.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.